These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23899335)

  • 21. Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.
    Budde LS; Hanna NH
    Expert Rev Anticancer Ther; 2004 Jun; 4(3):361-8. PubMed ID: 15161435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pemetrexed disodium (Eli Lilly).
    Norman P
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1611-22. PubMed ID: 11763166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [LY231514. A multitargeted antifolate (MTA)].
    Lansiaux A; Degardin M; Bailly C
    Bull Cancer; 1999 Sep; 86(9):727-31. PubMed ID: 10519965
    [No Abstract]   [Full Text] [Related]  

  • 25. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors.
    Adjei AA
    Ann Oncol; 2000 Oct; 11(10):1335-41. PubMed ID: 11106124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
    Ferraldeschi R; Thatcher N; Lorigan P
    Expert Rev Anticancer Ther; 2007 May; 7(5):635-40. PubMed ID: 17492928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positioning pemetrexed in the treatment of ovarian cancer.
    Ledermann JA; Stebbing J
    Eur J Cancer; 2009 May; 45(8):1330-2. PubMed ID: 19264477
    [No Abstract]   [Full Text] [Related]  

  • 29. Pemetrexed in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
    Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential role of pemetrexed in gastrointestinal cancer.
    Meriggi F; Di Biasi B; Caliolo C; Zaniboni A
    Chemotherapy; 2008; 54(1):1-8. PubMed ID: 18063861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of pemetrexed in lung cancer.
    Wang D; He J
    Curr Drug Targets; 2010 Jan; 11(1):1. PubMed ID: 20017724
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pemetrexed].
    Sudoh J; Gemma A
    Gan To Kagaku Ryoho; 2008 Jun; 35(6):1033-8. PubMed ID: 18633241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer.
    Hsu DS; Balakumaran BS; Acharya CR; Vlahovic V; Walters KS; Garman K; Anders C; Riedel RF; Lancaster J; Harpole D; Dressman HK; Nevins JR; Febbo PG; Potti A
    J Clin Oncol; 2007 Oct; 25(28):4350-7. PubMed ID: 17906199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pemetrexed in bladder, head and neck, and cervical cancers.
    Paz-Ares L; Ciruelos E; García-Carbonero R; Castellano D; Lopez-Martín A; Cortés-Funes H
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):69-75. PubMed ID: 12571815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of pemetrexed in breast cancer.
    Dittrich C
    Semin Oncol; 2006 Jun; 33(3 Suppl 9):S24-8. PubMed ID: 16797379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
    O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA
    Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pemetrexed therapy for malignant pleural mesothelioma.
    Puto K; Garey JS
    Ann Pharmacother; 2005 Apr; 39(4):678-83. PubMed ID: 15755794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second-line treatment for malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A
    Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.